Significant progress has been achieved in research on gliomas, MB, and lymphohematopoietic tumors involving the CNS, particularly regarding the targeting of antigens such as EGFRvIII, HER2, B7H3, GD2, and CD19. This evidence concerns the gene CD19 and glioma.